Abstract:The accumulation of extracellular amyloid-beta (Aβ), denoted as senile plaques, and intracellular neurofibrillary tangles (formed by hyperphosphorylated Tau protein) in the brain are two major neuropathological hallmarks of Alzheimer's disease (AD). The current and most accepted hypothesis proposes that the oligomerization of Aβ peptides triggers the polymerization and accumulation of amyloid, which leads to the senile plaques. Several strategies have been reported to target Aβ oligomerization/polymerization. Since it is thought that Aβ levels in the brain and peripheral blood maintain equilibrium, it has been hypothesized that enhancing peripheral clearance (by shifting this equilibrium towards the blood) might reduce Aβ levels in the brain, known as the sink effect. This process has been reported to be effective, showing a reduction in Aβ burden in the brain as a consequence of the peripheral reduction of Aβ levels. Nanoparticles (NPs) may have difficulty crossing the blood-brain barrier (BBB), initially due to their size. It is not clear whether particles in the range of 50-100 nm should be able to cross the BBB without being specifically modified for it. Despite the size limitation of crossing the BBB, several NP derivatives may be proposed as therapeutic tools. The purpose of this review is to summarize some therapeutic approaches based on nanoliposomes using two complementary examples: First, unilamellar nanoliposomes containing Aβ generic ligands, such as sphingolipids, gangliosides or curcumin, or some sphingolipid bound to the binding domain of ApoE; and second, nanoliposomes containing monoclonal antibodies against Aβ. Following similar rationale NPs of poly(lactide-co-glycolide)-poly (ethylene glycol) conjugated with curcumin-derivate (PLGA-PEG-B6/Cur) were reported to improve the spatial learning and memory capability of APP/PS1 mice, compared with native curcumin treatment. Also, some new nanostructures such as exosomes have been proposed as a putative therapeutic and prevention strategies of AD. Although the unquestionable interest of this issue is beyond the scope of this review article. The potential mechanisms and significance of nanoliposome therapies for AD, which are still are in clinical trials, will be discussed.

Biologically‐inspired ApoE3‐reconstituted high density lipoprotein: toward development of nanomedicines for alzheimer's disease (846.2)

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

Lipoprotein-Based Nanoparticles Rescue the Memory Loss of Mice with Alzheimer'S Disease by Accelerating the Clearance of Amyloid-Beta

Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery.

Lipoprotein-Inspired Nanoscavenger for the Three-Pronged Modulation of Microglia-Derived Neuroinflammation in Alzheimer’s Disease Therapy

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

The Shape Effect of Reconstituted High-Density Lipoprotein Nanocarriers on Brain Delivery and Aβ Clearance

High-density lipoprotein in Alzheimer's disease: From potential biomarkers to therapeutics

ApoE Lipidation as a Therapeutic Target in Alzheimer’s Disease

Dual-functional Nanoparticles for Precise Drug Delivery to Alzheimer’s Disease Lesions: Targeting Mechanisms, Pharmacodynamics and Safety

Biomembrane-Derived Nanoparticles in Alzheimer's Disease Therapy: A Comprehensive Review of Synthetic Lipid Nanoparticles and Natural Cell-Derived Vesicles

Biomembrane-Derived Nanoparticles in Alzheimer’s Disease Therapy: A Comprehensive Review of Synthetic Lipid Nanoparticles and Natural Cell-Derived Vesicles

Reassembly of Native Components with Donepezil to Execute Dual-Missions in Alzheimer's Disease Therapy

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

Gm1-Modified Lipoprotein-Like Nanoparticle: Multifunctional Nanoplatform for the Combination Therapy of Alzheimer'S Disease

Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's Disease

Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease

Endo/Lysosome‐Escapable Delivery Depot for Improving BBB Transcytosis and Neuron Targeted Therapy of Alzheimer's Disease

“Drug‐carrier” Synergy Therapy for Amyloid‐β Clearance and Inhibition of Tau Phosphorylation Via Biomimetic Lipid Nanocomposite Assembly

ApoE-modified liposomes encapsulating resveratrol and salidroside alleviate manifestations of Alzheimer's disease in APP/PS-1 mice